Pharmaceutical Executive, Jun 1, 2014 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Jun 1, 2014
Features
The Urge to Merge
Dealmaking lessons from history's storyboard.
Pharm Exec's Pharma 50 2014
By Waseem Noor
For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.
Promoting Adherence: From Force to Finesse
By Ben Comer
Non-adherence, in the US alone, is a $100-billion-a-year problem. Healthcare players are touting patient education and engagement as the keys to better adherence rates. Ben Comer reports.
Surviving the Emerging Market Price Wars: Three Myths & Three Lessons
How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment.
Column
Hopes High as EU Heads Into Leadership Change
By Reflector
Rare allies—innovator and generic pharmas—are calling for policy integration in Europe. But ideology and newfound scepticism on the merits of drugs in healthcare could complicate the effort.
Adaptive Trial Design: Prepping for Adoption
By Ken Getz
As interest grows in this productivity-enhancing tool for seamless drug development, there is a need for a better working consensus on standardized metrics that monitor progress and certify success.
Immunotherapies: The New Hope for Cancer Treatment
By Ben Comer
The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey
What Price Innovation?
By Jill Wechsler
Payers are seeking clear assessment of drug value to rationalize high drug prices. This issue has moved to center stage due to mounting concern over the high price for Gilead's Sovaldi, writes Jill Wechsler.
Compassionate Use Requests Complicate Drug Development
By Jill Wechsler
Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D.
Social Media and the In-House Counsel
What is and what should be keeping you up at night.
Challenges to the Specialty Business Model
New constraints require new solutions.
From the Editor
Pharma 50 Trends: Past, Present, and Future
By William Looney
Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.

ADVERTISEMENT

Click here